CHMP gives positive opinion for licence extension for brentuximab vedotin (Adcetris)

The CHMP have recommended a licence extension for brentuximab vedotin, in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adult patients with previously untreated systemic anaplastic large cell lymphoma.

European Medicines Agency